Skip to main content

Advertisement

SpringerLink
Log in

The Role of Sentinel Lymph Node Mapping in High-grade Endometrial Cancer

  • Gynecologic Cancers (JS Ferriss, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Total hysterectomy with lymph node assessment is the current standard-of-care for surgical staging in apparent early-stage endometrial cancer. Compared to the traditional complete pelvic lymphadenectomy with or without para-aortic lymphadenectomy, sentinel lymph node (SLN) mapping results in fewer surgical complications, decreased operative time, and lower rates of chronic lymphedema. The technique is endorsed by the National Comprehensive Cancer Network and the Society of Gynecologic Oncology guidelines, and over the past two decades the majority of gynecologic oncologists worldwide have adopted SLN mapping into their practice. However, as the results of the initial SLN studies were mostly based on low-grade tumors, adoption of the technique in high-grade tumors has been slower and more controversial. In this review, we discuss the most recent studies evaluating the SLN mapping in high-grade endometrial cancers. The results of these studies suggest that the SLN detection rate is acceptably high and the negative predictive value is sufficiently low to support the use of SLN mapping in high-grade endometrial tumors to replace complete lymphadenectomy. Validity of SLN mapping techniques does, however, require following a standard algorithm, and success depends also on surgeon expertise. Moreover, the impact of SLN mapping on overall survival in high-grade tumors requires future prospective randomized studies. Finally, a transition toward near-universal SLN mapping techniques for endometrial cancers could significantly impact on the adequacy of gynecologic oncology fellows’ surgical training and competency in lymphadenectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

  2. Smrz SA, Calo C, Fisher JL, Salani R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. Am J Obstet Gynecol. 2021;224(5):506–e1.

    Article  Google Scholar 

  3. Giaquinto AN, Broaddus RR, Jemal A, Siegel RL. The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol. 2022;139(3):440–2.

    Article  Google Scholar 

  4. Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019;38(1 Suppl 1):S40.

    Article  Google Scholar 

  5. Foote JR, Gaillard S, Broadwater G, Sosa JA, Davidson B, Adam MA, Secord AA, Jones MB, Chino J, Havrilesky LJ. Disparities in the surgical staging of high-grade endometrial cancer in the United States. Gynecol Oncol Res Pract. 2017;4(1):1–8.

    Article  Google Scholar 

  6. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506–19.

    Article  CAS  Google Scholar 

  7. Panici PB, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. JNCI: J Natl Cancer Inst. 2008;100(23):1707–16.

    Article  Google Scholar 

  8. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (London, England). 2008;373(9658):125–36.

    Google Scholar 

  9. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987;60(S8):2035–41.

    Article  CAS  Google Scholar 

  10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) – Uterine Neoplasms Version 1.2022 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Center (US); 2021 Nov 4 [cited 2022, May 23]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

  11. Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Lowery WJ, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017;146(2):405–15.

    Article  Google Scholar 

  12. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–85.

    Article  Google Scholar 

  13. Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol. 1996;62(2):169–73.

    Article  CAS  Google Scholar 

  14. Capozzi VA, Riemma G, Rosati A, Vargiu V, Granese R, Ercoli A, Cianci S. Surgical complications occurring during minimally invasive sentinel lymph node detection in endometrial cancer patients. A systematic review of the literature and metanalysis. Eur J Surg Oncol. 2021;47(8):2142–9.

    Article  Google Scholar 

  15. Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Khoury-Collado F, Hershman DL, Wright JD. Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer. BJOG. 2022;129(9):1591–1599. https://doi.org/10.1111/1471-0528.17085

  16. Diniz TP, Drizlionoks E, Faloppa CC, Menezes JN, Mantoan H, Gonçalves BT, Brandao PH, Kumagai LY, Badiglian-Filho L, da Costa AA, Baiocchi G. Impact of sentinel node mapping in decreasing the risk of lymphocele in endometrial cancer. Ann Surg Oncol. 2021;28(6):3293–9.

    Article  Google Scholar 

  17. Glaser G, Dinoi G, et al. Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer. Int J Gynecol Cancer. 2021;31(1):85–91.

    Article  Google Scholar 

  18. Holloway RW, Gupta S, Stavitzski NM, Zhu X, Takimoto EL, Gubbi A, Bigsby GE, Brudie LA, Kendrick JE, Ahmad S. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol. 2016;141(2):206–10.

    Article  Google Scholar 

  19. Raimond E, Ballester M, Hudry D, Bendifallah S, Daraï E, Graesslin O, Coutant C. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol. 2014;133(3):506–11.

    Article  Google Scholar 

  20. Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, Daraï E. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12(5):469–76.

    Article  Google Scholar 

  21. Gómez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St. Clair CM, Ananth CV, Hershman DL, Wright JD. Trends in sentinel lymph node mapping and adjuvant therapy in endometrial carcinoma. Cancer Investig. 2018;36(3):190–8.

    Article  Google Scholar 

  22. Rossi EC, Tanner E. Controversies in sentinel lymph node biopsy for gynecologic malignancies. J Minim Invasive Gynecol. 2021;28(3):409–17.

    Article  Google Scholar 

  23. Chambers LM, Vargas R, Michener CM. Sentinel lymph node mapping in endometrial and cervical cancer: a survey of practices and attitudes in gynecologic oncologists. J Gynecol Oncol. 2019;30(3).

  24. Rossi EC, Jackson A, Ivanova A, Boggess JF. Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. Int J Gynecol Cancer. 2013;23(9).

  25. Barlin JN, Khoury-Collado F, Kim CH, Leitao MM Jr, Chi DS, Sonoda Y, Alektiar K, DeLair DF, Barakat RR, Abu-Rustum NR. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125(3):531–5.

    Article  Google Scholar 

  26. How J, Gotlieb WH, Press JZ, Abitbol J, Pelmus M, Ferenczy A, Probst S, Gotlieb R, Brin S, Lau S. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol. 2015;137(3):436–42.

    Article  CAS  Google Scholar 

  27. Holloway RW, Ahmad S, Kendrick JE, Bigsby GE, Brudie LA, Ghurani GB, Stavitzski NM, Gise JL, Ingersoll SB, Pepe JW. A prospective cohort study comparing colorimetric and fluorescent imaging for sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol. 2017;24(7):1972–9.

    Article  Google Scholar 

  28. Papadia A, Gasparri ML, Buda A, Mueller MD. Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue. J Cancer Res Clin Oncol. 2017;143(10):2039–48.

    Article  CAS  Google Scholar 

  29. Cabrera S, Barahona-Orpinell M, Almansa-González C, Padilla-Iserte P, Bebia V, Martí L, Tejerizo-García Á, Domingo S, Gil-Moreno A. Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: results of the COMBITEC study. Gynecol Oncol. 2021;162(1):32–7.

    Article  CAS  Google Scholar 

  30. Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, Sonoda Y, Hensley ML, Barakat RR, Abu-Rustum NR. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer. 2013;23(5).

  31. Burg LC, Hengeveld EM, Bulten J, Bult P, Zusterzeel PL. Ultrastaging methods of sentinel lymph nodes in endometrial cancer–a systematic review. Int J Gynecol Cancer. 2021;31(5).

  32. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017;146(2):234–9.

    Article  Google Scholar 

  33. Wang T, Hu Y, He Y, Sun P, Guo Z. A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Arch Gynecol Obstet. 2019;299(5):1429-35. This retrospective study provided further validation on the validity of SLN mapping in high-risk endometrial cancers in a Chinese cohort.

  34. Persson J, Geppert B, Lönnerfors C, Bollino M, Måsbäck A. Description of a reproducible anatomically based surgical algorithm for detection of pelvic sentinel lymph nodes in endometrial cancer. Gynecol Oncol. 2017;147:120–5.

    Article  Google Scholar 

  35. Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, Laframboise S, May T, Hogen LF, Covens AL, Gien LT. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate-and high-grade endometrial cancer staging. JAMA Surg. 2021;156(2):157-64. The SENTOR study is a key prospective study that looked at validity of sentinel lymph node mapping compared to lymphadenectomy with a majority high-grade study population (n=126/156).

  36. Papadia A, Gasparri ML, Radan AP, Stämpfli CA, Rau TT, Mueller MD. Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer. J Cancer Res Clin Oncol. 2018;144(7):1385–93.

    Article  CAS  Google Scholar 

  37. Altin D, Taşkın S, Ortaç F, Tokgözoğlu N, Vatansever D, Güler AH, Güngör M, Taşçı T, Beşe T, Turan H, Kahramanoğlu İ. Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: a Turkish gynecologic oncology group study (TRSGO-SLN-006). Gynecol Oncol. 2022. A recent retrospective study of a Turkish cohort of high-grade endometrial cancer patients (n=128) that continues to validate the acceptability of sentinel lymph node mapping in high-grade tumors.

  38. Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, Bouchard-Fortier G, Rossi EC, Stewart KI, Soliman PT, How JA. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021;225(4):367-e1. The first meta-analysis of the validity of SLN mapping in exclusively high-grade endometrial cancer and combines data from 9 studies (n=429) using a systematic review from January 1, 2000 to January 26, 2021.

  39. Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, Method M, Ade M, Ivanova A, Boggess JF. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384–92.

    Article  Google Scholar 

  40. Persson J, Salehi S, Bollino M, Lönnerfors C, Falconer H, Geppert B. Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)—the final step towards a paradigm shift in surgical staging. Eur J Cancer. 2019;116:77-85. This trial was one of the first prospective studies to look at validity measures using SLN mapping in high-grade endometrial cancers.

  41. Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C. Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol. 2015;138(2):478–85.

    Article  Google Scholar 

  42. Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Keeney GL, Thomas G, Mariani A. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol. 2014;132(1):38–43.

    Article  Google Scholar 

  43. Li W, Jiang J, Fu Y, Shen Y, Zhang C, Yao S, Xu C, Xia M, Lou G, Liu J, Lin B. Implications of isolated para-aortic lymph node metastasis in endometrial cancer: a large-scale, multicenter, and retrospective study. Front Med. 2021;8.

  44. Nasioudis D, Albright BB, Roy A, Ko EM, Giuntoli RL, Haggerty AF, Cory L, Kim SH, Morgan MA, Latif NA. Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer. Gynecol Oncol. 2020;159(3):732-6. Using information from the National Cancer Database, this study characterizes increased use of SLN mapping for patients with high-grade endometrial cancer. It also demonstrates comparable survival for those undergoing SLN mapping compared to systematic lymphadenectomy.

  45. Multinu F, Casarin J, et al. Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer. Gynecol Oncol. 2019;154:60–4.

    Article  Google Scholar 

  46. Schlappe BA, Weaver AL, McGree ME, Ducie J, Eriksson AG, Dowdy SC, Cliby WA, Glaser GE, Abu-Rustum NR, Mariani A, Leitao Jr MM. Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol. 2020;156(1):62-9. This retrospective study demonstrates comparable survival outcomes for patients with serous and clear cell endometrial carcinoma comparing those who had SLN mapping following algorithm versus complete lymphadenectomy.

  47. Basaran D, Bruce S, Aviki EM, Mueller JJ, Broach VA, Cadoo K, Soslow RA, Alektiar KM, Abu-Rustum NR, Leitao Jr MM. Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecol Oncol. 2020;156(1):70-6. This retrospective study of patients with uterine serous carcinoma found no survival benefit for those receiving systematic lymphadenectomy versus sentinel lymph node mapping.

  48. Schiavone MB, Zivanovic O, Zhou Q, Leitao MM, Levine DA, Soslow RA, Alektiar KM, Makker V, Iasonos A, Abu-Rustum NR. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2016;23(1):196–202.

    Article  Google Scholar 

  49. Baiocchi G, Andrade CE, Ribeiro R, Moretti-Marques R, Tsunoda AT, Alvarenga-Bezerra V, Lopes A, Costa RL, Kumagai LY, Badiglian-Filho L, Faloppa CC. Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial). Int J Gynecol Cancer. 2022;32(5).

  50. Obermair A, Nicklin J, Gebski V, Hayes SC, Graves N, Mileshkin L, Lin MY, Beale P, Baxter E, Robledo K, Salomon C, Hanna GB, Janda M. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020. Int J Gynecol Cancer. 2021;31(12):1595–601. https://doi.org/10.1136/ijgc-2021-003029.

    Article  PubMed  Google Scholar 

  51. Matsuo K, Klar M, Nusbaum DJ, Hasanov MF, Vallejo A, Ciesielski KM, Muderspach LI, Roman LD, Wright JD. Utilization and outcomes of sentinel lymph node biopsy for early endometrial cancer. Obstet Gynecol. 2022;139(5):809-20. This data using the National Cancer Institute’s SEER database provides changes over time on the uptake of sentinel lymph node mapping and discusses factors impacting its uptake such as histology.

  52. Casarin J, Multinu F, Abu-Rustum N, Cibula D, Cliby WA, Ghezzi F, Leitao M, Konishi I, Nam JH, Querleu D, Soliman PT. Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. Int J Gynecol Cancer. 2019;29(1).

  53. Aarts JW, Burg LC, Kasius JC, Groenewoud H, Kraayenbrink AA, Stalmeier P, Zusterzeel PL. Patients’ and gynecologists' views on sentinel lymph node mapping in low-and intermediate-risk endometrial cancer: a Dutch vignette study. Int J Gynecol Cancer. 2020;30(6).

  54. Renz M, Diver E, English D, Kidd E, Dorigo O, Karam A. Sentinel lymph node biopsies in endometrial cancer: practice patterns among gynecologic oncologists in the United States. J Minim Invasive Gynecol. 2020;27(2):482–8.

    Article  Google Scholar 

  55. Togami S, Kobayashi H, Niikura H, Shimada M, Susumu N, Tanaka T, Terai Y, Nagai T, Baba T, Yahata H, Yamagami W. Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study. Int J Clin Oncol. 2021;26(5):971–9.

    Article  CAS  Google Scholar 

  56. Accreditation Council for Graduate Medical Education. ACGME Program Requirements for Graduate Medical Education in Gynecologic Oncology [Internet]. Chicago (IL): Accreditation Council for Graduate Medical Education (US); 2020 [updated 2020, June 13; cited 2022, May 23]. Available from: https://www.acgme.org/globalassets/pfassets/programrequirements/225_gynecologiconcology_2020.pdf

  57. Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, Soslow RA, Dao F, Sonoda Y, Levine DA, Brown CL, Chi DS, Barakat RR, Gemignani ML. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol. 2009;113(2):163–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Ruoxi Yu MPH

  2. Department of Gynecology and Obstetrics, The Kelly Gynecologic Oncology Service, Johns Hopkins Medicine, 600 North Wolfe Street, Phipps 281, Baltimore, MD, 21287, USA

    Ruoxi Yu MPH, Benjamin J. Matthews MD & Anna L. Beavis MD, MPH

Authors
  1. Ruoxi Yu MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin J. Matthews MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna L. Beavis MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna L. Beavis MD, MPH.

Ethics declarations

Conflict of Interest

The authors report no potential conflicts of interest relevant to this article.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, R., Matthews, B.J. & Beavis, A.L. The Role of Sentinel Lymph Node Mapping in High-grade Endometrial Cancer. Curr. Treat. Options in Oncol. 23, 1339–1352 (2022). https://doi.org/10.1007/s11864-022-00999-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-022-00999-5

Keywords

Search

Navigation